A national French noninterventional study to assess the long‐term safety and efficacy of reformulated nonacog alfa

Nonacog alfa, the recombinant Factor IX (F IX) used for the treatment of hemophilia B, was approved in Europe in 1998. A reformulated version was approved for European use in 2007.

[1]  C. Rothschild,et al.  EQOFIX: a combined economic and quality‐of‐life study of hemophilia B treatments in France , 2015, Transfusion.

[2]  L. Valentino,et al.  Multicentre, randomized, open‐label study of on‐demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  S. Björkman.  Pharmacokinetics of plasma‐derived and recombinant factor IX – implications for prophylaxis and on‐demand therapy , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  M. Makris,et al.  A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  M. Recht,et al.  A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  Divya Mishra,et al.  Non interventional drug studies in oncology: Why we need them? , 2010, Perspectives in clinical research.

[8]  P. Monahan,et al.  Safety and efficacy of investigator‐prescribed BeneFIX® prophylaxis in children less than 6 years of age with severe haemophilia B , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  D. DiMichele.  Inhibitor development in haemophilia B: an orphan disease in need of attention , 2007, British journal of haematology.

[10]  L. Valentino,et al.  Reformulated BeneFix®: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  V. Blanchette,et al.  The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. , 2005, Blood.

[12]  M. Haase.  Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. , 2002, Blood.